12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zybrestat fosbretabulin: Phase II ongoing

OxiGene said the Gynecologic Oncology Group will continue enrollment in the open-label, U.S. Phase II GOG 186I trial of Zybrestat plus Avastin bevacizumab after a safety review committee observed no additional pre-specified safety concerns in the second and final interim toxicity analysis from the first 53 evaluable patients. The trial is comparing Zybrestat plus...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >